^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug Class: | T-lymphocyte cell therapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies
Published date:
11/01/2018
Excerpt:
Between March 2016 and January 2018, a total of 89 eligibility pts completed CAR-22/19 "cocktail" infusion and were included for analysis. Of 89 pts (median age 36 years; range, 9-71), 51 had refractory/relapsed (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and 38 had R/R B-cell non-Hodgkin lymphoma (B-NHL)....At a minimum follow-up of 3 months, the overall response rate (ORR) and CR rate in 36 evaluable B-NHL pts was 72.2% and 50%, respectively….Of the 10 pts with del(17p) or TP53 mutation, 8 (80.0%) had a clinical response.
DOI:
https://doi.org/10.1182/blood-2018-99-113714
